COVID-19 Breaking News
-
BD Ramps Up Manufacturing Capacity
10.08.21
New manufacturing lines to provide U.S. govt. with access to hundreds of millions of needles and syringes to support U.S. vaccination agility and preparedness.
-
TriLink Extends EyeGene Partnership for COVID-19 Vaccine Development
10.05.21
CleanCap technology to be used in the production of EG-COVID mRNA COVID-19 vaccine for clinical trials.
-
Moderna to Invest in Science Center
10.05.21
462,000 square foot state-of-the-art building targeting LEED Zero certification and designed to be the most sustainable commercial lab building in Cambridge, MA
-
Veklury Reduced Risk of Hospitalization in High-Risk COVID-19 Patients
09.22.21
Veklury demonstrated a statistically significant 87% reduction in risk for the composite primary endpoint of COVID-19 related hospitalization.
-
Lilly’s Antibody Treatment Gets EUA for Post-Exposure COVID Prevention
09.17.21
Phase 3 study shows bamlanivimab 4200 mg reduced the risk of contracting symptomatic COVID-19 by up to 80 percent in nursing home residents.
-
Tevogen Completes Tech Transfer to CDMO BioCentriq
09.16.21
Reaches commercial manufacturing readiness milestone for its investigational COVID-19 therapy TVGN-489.
-
BioVaxys Reports Progress on Covid-19 Vax Candidate
09.16.21
Bioproduction partner Wuxi Biologics completes synthesis of recombinant SARS-CoV-2 s-proteins for BVX-0320 and CoviDTH programs.
-
U.S. Govt. to Purchase Additional Doses of REGEN-COV Antibody Cocktail
09.15.21
Will supply an additional 1.4 million 1,200 mg doses of REGEN-COV to the U.S. government by January 31, 2022.
-
U.S. Govt. Purchases Additional Doses of Lilly's Antibody Therapies for COVID
09.15.21
Will supply 388,000 doses of etesevimab to complement doses of bamlanivimab previously purchased, with approximately 200,000 doses expected to ship 3Q21.
-
Emergent BioSolutions, Providence Therapeutics Enter Vaccine Manufacturing Partnership
09.14.21
Ink multi-year development and manufacturing agreement for mRNA COVID-19 vaccine candidate, PTX-COVID19-B.
-
Maintaining Critical Drug Supply During COVID-19
Tim Wright, Editor, Contract Pharma || 09.09.21
Vincent Colicchio from Dr. Reddy’s talks about the challenges and solutions of maintaining supply during the pandemic.
-
Resilience to Manufacture mRNA for Moderna’s COVID-19 Vaccine
09.08.21
Will produce mRNA at its Canadian facility in Mississauga, Ontario.
-
SignalRx, Crystec and ADYA Partner to Develop Treatment for SARS-CoV-2 Related Illnesses
08.26.21
Aim to develop an inhaled dry powder formulation of SF2523.
-
Pfizer, BioNTech Collaborate with Brazil’s Eurofarma to Manufacture Covid-19 Vaccines
08.26.21
The annual production is expected to exceed 100 million finished doses annually for Latin America.
-
FDA Approves Pfizer-BioNTech COVID-19 Vaccine COMIRNATY
08.23.21
Grants first full approval for COVID vaccine.
-
Akston Biosciences, Seppic Ink Commercial Supply Agreement
07.29.21
Deal is for an adjuvant to formulate shelf-stable COVID-19 vaccine at global scale.
-
Batavia to Develop Clinical Process for RocketVax’s COVID-19 Vaccine
07.08.21
After successful completion, Batavia will continue to scale-up and optimize the process for commercial scale.
-
Swiss Government Turns to Swissfillon for COVID-19 Test Kit Production
07.08.21
Drug product CMO specialist adapts to provide 0.8 million prefilled syringes.
-
The Power and Promise of Decentralized Trials
Derk Arts, CEO, Castor || 06.25.21
Clinical researchers turned to a range of digital solutions to address the effects of the COVID-19 pandemic on trials.
-
AbCellera to Build Antibody Manufacturing Facility in Canada
06.23.21
130,000-square-foot Vancouver facility aims to accelerate the development of antibody-based therapies for an array of medical conditions.
